WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Bridgette P. Heller net worth and biography

Bridgette Heller Biography and Net Worth

Director of DexCom

Bridgette Heller has served on the Board since September 2019. Ms. Heller brings to our Board considerable experience in business, specifically as it relates to technology and manufacturing, and she is a strong addition to the Board as Dexcom continues to expand and scale its operations.

Ms. Heller is a co-founder and the CEO of a small nonprofit, the Shirley Proctor Puller Foundation, committed to generating better educational outcomes for underserved children in St. Petersburg, Florida. Previously, Ms. Heller served as the EVP and President of Nutricia, the Specialized Nutrition Division of Danone from July 2016 to August 2019. From 2010 to 2015, she served as Executive Vice President of Merck & Co., Inc. and President of Merck Consumer Care. Prior to joining Merck, Ms. Heller was President of Johnson & Johnson’s Global Baby Business Unit from 2007 to 2010 and President of its Global Baby, Kids, and Wound Care business from 2005 to 2007. She also worked for Kraft Foods from 1985 to 2002, ultimately serving as Executive Vice President and General Manager for the North American Coffee Portfolio.

Ms. Heller also serves on the Boards of Novartis and Tech Data Corporation.

She holds an MBA from Northwestern University’s Kellogg Graduate School of Management and is a member of the school’s Advisory Board. Ms. Heller received her bachelor’s degree in Economics and Computer Studies from Northwestern University.

What is Bridgette P. Heller's net worth?: The estimated net worth of Bridgette P. Heller is at least $2.03 million as of June 14th, 2024. Heller owns 25,349 shares of DexCom stock worth more than $2,028,934 as of December 21st. This net worth estimate does not reflect any other investments that Heller may own. Learn More about Bridgette P. Heller's net worth.
How do I contact Bridgette P. Heller?: The corporate mailing address for Heller and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Bridgette P. Heller's contact information.
Has Bridgette P. Heller been buying or selling shares of DexCom?: Bridgette P. Heller has not been actively trading shares of DexCom in the last ninety days. Learn More on Bridgette P. Heller's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 24 times. They sold a total of 248,077 shares worth more than $32,452,099.04. The most recent insider tranaction occured on November, 20th when EVP Sadie Stern sold 4,259 shares worth more than $318,275.07. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 11/20/2024.

Bridgette P. Heller Insider Trading History at DexCom

Bridgette P. Heller Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $80.04

$75.47

$81.51

50 Day Range

MA: $74.53

$67.10

$81.01

2 Week Range

Now: $80.04

$62.34

$142.00

Volume

11,494,120 shs

Average Volume

3,910,878 shs

Market Capitalization

$31.26 billion

P/E Ratio

47.93

Dividend Yield

N/A

Beta

1.12